Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxP Villin-Cre mice

Conclusions Mesalazine and thymoquinone reduce tumour incidence and multiplicity in Msh2loxP/loxP Villin-Cre mice by reduction of MSI independent of a functional mismatch repair system. Both substances are candidate compounds for chemoprevention in Lynch syndrome mutation carriers.

http://gut.bmj.com/cgi/content/short/64/12/1905?rss=1

Source: Gut - November 8, 2015 Category: Gastroenterology Authors: Kortüm, B., Campregher, C., Lang, M., Khare, V., Pinter, M., Evstatiev, R., Schmid, G., Mittlböck, M., Scharl, T., Kucherlapati, M. H., Edelmann, W., Gasche, C. Tags: Open access, Editor's choice, Colon cancer GI cancer Source Type: research